SANTA CRUZ BIOTECHNOLOGY, INC.

ATIII (m): 293T Lysate: sc-118611

BACKGROUND

The serine proteinase inhibitors (serpins) compose a superfamily of proteins with a diverse set of functions, including the control of blood coagulation, complement activation, programmed cell death and development. Serpins are secreted glycoproteins that contain a stretch of peptide that mimics a true substrate for a corresponding serine protease. Antithrombin III (ATIII), an extracellular plasma protein, is a crucial serine protease inhibitor that regulates the coagulation cascade in blood. The inhibitory activity of ATIII is amplified in the presence of heparin. ATIII inhibits Thrombin and Factors IX A, X A and XI A. Defects in the gene SERPINC1, which encodes for ATIII, can cause ATIII deficiency, an autosomal dominant disease, which is a risk factor for hereditary thrombophilia.

REFERENCES

1. Mackie, M., Bennett, B., Ogston, D. and Douglas, A.S. 1978. Familial thrombosis: inherited deficiency of antithrombin III. Br. Med. J. 21: 136-138.
2. Scully, M.F., De Haas, H., Chan, P. and Kakkar, V.V. 1981. Hereditary antithrombin III deficiency in an English family. Br. J. Haematol. 47: 235-240.
3. Winter, J.H., Fenech, A., Bennett, B. and Douglas, A.S. 1981. Transfusion studies in patients with familial antithrombin III (ATIII) deficiency: half-disappearance time of infused ATIII and influence of such infusion on platelet life-span. Br. J. Haematol. 49: 449-453.
4. Okajima, K., Abe, H., Wagatsuma, M., Okabe, H. and Takatsuki, K. 1995. Antithrombin III Kumamoto II; a single mutation at Arg393-His increased the affinity of ATIII for heparin. Am. J. Hematol. 48: 12-18.
5. Bayston, T.A., Tripodi, A., Mannucci, P.M., Thompson, E., Ireland, H., Fitches, A.C., Hananeia, L., Olds, R.J. and Lane, D.A. 1999. Familial overexpression of β AT caused by an Asn 135-Thr substitution. Blood 93: 4242-4247.
6. Yeung, PK. 2000. Transgenic ATIII (Genzyme). IDrugs 3: 669-673.
7. Niiya, K., Kiguchi, T., Dansako, H., Fujimura, K., Fujimoto, T., Iijima, K., Tanimoto, M. and Harada, M. 2001. Two novel gene mutations in type I AT deficiency. Int. J. Hematol. 74: 469-472.
8. Duru, S., Koca, U., Oztekin, S., Olguner, C., Kar, A., Coker, C., Ulukus, C., Tasci, C. and Elar, Z. 2005. ATIII pretreatment reduces neutrophil recruitment into the lung and skeletal muscle tissues in the rat model of bilateral lower limb ischemia and reperfusion: a pilot study. Acta Anaesthesiol. Scand. 49: 1142-1148.
9. Cassar, K., Bachoo, P., Ford, I., Greaves, M. and Brittenden, J. 2005. Clopidogrel has no effect on D-dimer and Thrombin-ATIII levels in patients with peripheral arterial disease undergoing peripheral percutaneous transluminal angioplasty. J. Vasc. Surg. 42: 252-258.

STORAGE

Store at -20° C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

CHROMOSOMAL LOCATION

Genetic locus: Serpinc1 (mouse) mapping to 1 H2.1.

PRODUCT

ATIII (m): 293T Lysate represents a lysate of mouse ATIII transfected 293T cells and is provided as 100 µg protein in 200 µl SDS-PAGE buffer.

APPLICATIONS

ATIII (m): 293T Lysate is suitable as a Western Blotting positive control for mouse reactive ATIII antibodies. Recommended use: 10-20 µl per lane.

Control 293T Lysate: sc-117752 is available as a Western Blotting negative control lysate derived from non-transfected 293T cells.

RESEARCH USE

For research use only, not for use in diagnostic procedures.